Projet SYNDEGEN (Horizon 2020, appel à projets 2016)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are sites of early and aberrant protein misfolding, aggregation and spread in NDDs. A key problem in research on NDDs has been that the normal physiological roles at synapses of the aggregation-prone proteins (β- amyloid/amyloid precursor protein, tau, α-synuclein and huntingtin), which are linked pathologically and genetically to these diseases, are not known. Using cutting-edge technologies and multidisciplinary approaches the SYNDEGEN consortium aims to bring together leading experts in cell biology, synapse biology and imaging, stem cell biology and NDDs in Europe to determine the molecular and cellular mechanisms whereby synapses become dysfunctional in AD, PD and HD for the purpose of developing novel therapies. The goal of the consortium is to train talented young scientists in interdisciplinary, innovative and collaborative research aimed at the development of novel molecular based treatment strategies for these major diseases of aging. A gap in the training of students in these important diseases is that disease expertise and novel methods to study synapses are localized in isolated groups in different locations in the EU. Similar questions are being asked about the mechanisms of synaptic dysfunction in AD, PD and HD, but no one university or company has sufficiently broad knowledge and technical expertise required to study and develop therapies for synaptic dysfunction in these disorders. This training programme will be implemented in 6 academic centres and 2 SMEs representing a comprehensive, highly interactive and multidisciplinary partnership.

Mots clés : neurodegenerative diseases, synapse, ageing, alzheimer s disease, parkinson s disease, huntington s disease, synaptic plasticity, endosomes, neuropathology

Participants :
- University Hospital of Umeå (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 263659.32 €
- Universitätsmedizin Göttingen (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- Explora nova (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Ulm (Allemagne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- German Center for Neurodegenerative Diseases (Allemagne) — Partner, beneficiary, Recherche, subvention : 498432.96 €
- NeuroProof (Germany) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Board of the Swiss Federal Institutes of Technology (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265226.76 €
- Swedish Parkinson’s Disease Association (Suède) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Cambridge (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 273287.88 €
- Lund University (Suède) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 790977.96 €
- Umeå University (Suède) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Centre national de la recherche scientifique (France) — Partner, beneficiary, Recherche, subvention : 788626.8 €
- Lundbeck (Denmark) (Danemark) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Scania Regional Council (Suède) — Partner, organization partner, Organismes publics (hors enseignement & recherche), subvention : 0.0 €